Hospital care costs are out of control. Price caps can help.
By Andy Ryan and Roslyn Murray of Brown University
Genomic databases help doctors and researchers interpret our genes.
Disciplines:
MedicineChrista Lese Martin, Ph.D., FACMG, is the Director of the Autism and Developmental Medicine Institute and Senior Investigator at Geisinger Health System. Previously, Dr. Martin was an Associate Professor at Emory University and Senior Lab Director of the Emory Genetics Lab. Her research interests include the identification and characterization of chromosomal imbalances involved in neurodevelopmental disorders and the rapid translation of new technologies for copy-number variation detection into the diagnostic arena for postnatal and prenatal testing.
Disciplines:
BiologyChris graduated from Sarah Lawrence College in 2007 with a Master of Science in Human Genetics and was certified by the American Board of Genetic Counseling in 2009. He joined the University of Chicago as a Genetic Counselor in 2007, where his responsibilities covered general pediatrics, prenatal, newborn screening, and laboratory counseling. Over the years, he has also been involved in a variety of specialty clinics, including ophthalmology and neurogenetics. He is currently the Senior Genetic Counselor for the University of Chicago Genetic Services, an academic DNA diagnostic laboratory that tests rare orphan genetic diseases.
Disciplines:
Biology & MedicineErin Rooney Riggs, MS, CGC is a certified genetic counselor at Geisinger Health System's Autism and Developmental Medicine Institute and the co-coordinator of the International Collaboration for Clinical Genomics (ICCG). Previously, she served as a clinical genetic counselor at Emory University School of Medicine, focusing on general pediatrics and lysosomal storage disorders. Her research interests include the identification and characterization of the genetic causes of neurodevelopmental disorders, the effects of gene dosage, and the clinical utility of genomic testing.
Disciplines:
MedicineHeidi Rehm, Ph.D., FACMG is the Chief Laboratory Director of the Laboratory for Molecular Medicine (LMM) at the Partners Healthcare Center for Personalized Genetic Medicine (PCPGM). She is a board-certified clinical molecular geneticist and Associate Professor of Pathology at Harvard Medical School with appointments at Brigham and Women's Hospital, Massachusetts General Hospital, and Children’s Hospital Boston. Dr. Rehm has served as the Director of the American Board of Medical Genetics' Clinical Molecular Genetics Training Program at Harvard Medical School since 2006. In addition to running the LMM and the molecular training program, she also conducts research on hearing loss, Usher syndrome, cardiomyopathy, and the use of IT in enabling personalized medicine.
Disciplines:
BiologyKaren received a degree in biology from Luther College (Decorah, IA) in 2000 and a Master of Science degree in Human Genetics, Genetic Counseling from the University of Michigan in 2007. She is a genetic counselor in the Mayo Clinic Cytogenetics Laboratory. In addition, she is a member of the Education, Engagement, and Ethics Workgroup and the Structural Variation Workgroup for the International Collaboration for Clinical Genomics (ICCG). She also provides genetic counseling services for patients with Hereditary Hemorrhagic Telangiectasia (HHT) and chromosome anomalies. Her research interests include psychosocial issues in genetic counseling, adult and pediatric clinical genetics, HHT, and cytogenetics.
Disciplines:
MedicinePatti Krautscheid is a certified genetic counselor with ARUP Laboratories, a national clinical reference laboratory and an enterprise of the University of Utah's Department of Pathology. She specializes in clinical molecular and genomic testing for inherited disorders. Krautscheid has an M.S. in Genetic Counseling from University of Michigan and a B.S. in Biology from University of Wisconsin–LaCrosse.
By Heidi Rehm, Christa Martin, Erin Riggs, Christopher Tan, Patti Krautscheid & Karen Wain, International Collaboration for Clinical Genomics
Once an enormous undertaking requiring years of effort and billions of dollars, it is now possible to sequence an entire human genome in approximately two days for about $1,000.(a) The ease with which we can now obtain genomic information has the potential to transform medicine, allowing doctors to more accurately diagnose diseases and tailor treatment to suit an individual’s genomic profile.
Unfortunately, our ability to acquire genetic data has significantly outpaced our capacity to interpret and use it. In the current medical landscape, scenarios like the following are not uncommon:
After waiting months to get a medical genetics appointment and then weeks to hear the results, a family is hopeful for answers about their two-year-old son’s mysterious developmental problems. He was born with a heart abnormality and a missing kidney, and as he grew up, he appeared different from other children and was not meeting developmental milestones. His doctors determine that he has a rare chromosome deletion, but cannot say whether or how it is related to his condition because they aren’t aware of anyone else with this genetic abnormality. While they may have found a clue in the child’s genome, they don’t yet have the tools or information to understand what it means.
Everyone has variants in their genetic code like this child, but only some are associated with health problems – the rest constitute normal human genetic variation.(b) In order to decipher the true meaning of genetic variants, large amounts of information — more than any one laboratory alone can generate — must be collected and shared by laboratories, clinicians, and researchers. Genetic databases address this problem by aggregating genetic test results to catalogue gene variants.
While it may be years before we fully understand rare conditions like the one suffered by the child in the story above, access to a genetic database could help his doctors identify other children with the same genetic variant, determine if they have similar symptoms, and learn about treatments and therapies that have worked for these patients. In the long run, databases can also assist researchers seeking to understand a gene’s role in a particular disease. They will help the medical community transition from merely possessing massive amounts of genomic data to understanding and using this information.
Deciphering the Secrets in Our DNA
Researchers and clinicians have just scratched the surface in understanding how individual genes cause traditional “genetic diseases” like cystic fibrosis or sickle cell anemia (genetics), as well as how multiple genes in an individual’s genome contribute to complex diseases like diabetes and cardiovascular disease.(c) Only about 4,000 of the estimated 20,000 genes in the human genome have been linked to specific diseases.1 Even genes that have been studied for many years, such as the CFTR gene associated with cystic fibrosis, are not fully understood. Since discovering CFTR in 1989, scientists have learned a great deal about specific variants of the gene and how they cause disease, but there are still numerous variants that cannot be clearly categorized as disease-causing (pathogenic) or harmless (benign).2
While researchers continue to conduct large-scale studies on how genes affect health and cause disease, doctors are beginning to incorporate genomic data into clinical practice. When they see patients with health issues that may have an underlying genetic cause, clinicians often order testing of specific genes, a set of genes, or the patient’s entire genome. The resulting genetic information may be used to make or confirm a diagnosis, advise a patient on their prognosis, determine the most effective course of treatment, or decide how a patients’ health should be monitored and what other tests they should receive. Test results are also used in genetic counseling to determine whether other family members are at risk for a disease.(d)
Because genetic test results can be used to make important determinations about patient care, thorough and accurate interpretation of test results is critical. Incorrect interpretations can result in misdiagnosis, prompting unnecessary monitoring, procedures, treatments, and stress for individuals and their family members. This is especially problematic for individuals who have predictive testing when few or no signs or symptoms of disease are present; without symptoms, medical decisions may be based largely on the genetic test results.
The clinical laboratories that conduct genetic tests often play a significant role in the interpretation of findings, with laboratory scientists identifying and analyzing hundreds of thousands of genomic variants per year. The laboratory’s interpretation helps the clinician understand what impact, if any, a genomic variant may have on a patient’s health. But interpreting the human genome is not a simple task: genes have different structures and functions, the specific types of variants that cause disease differ from one gene to the next, and the ways variants are inherited or transmitted can vary.(e) Clinical laboratory professionals therefore spend significant amounts of time researching variants by consulting the medical literature and proprietary genomic databases.
While professional guidelines offer a loose framework to help laboratories determine the significance of genomic variants, a good deal of subjectivity remains, and even two highly competent laboratory professionals may interpret the same genetic variant differently.3 As more laboratories test patients’ entire genomes, they will encounter variants that they have little experience interpreting, most of which have not been extensively studied by researchers. When unable to determine if a genetic variant is the cause of a disease, the laboratory may report uncertainty about the result. Due to the many sources of variation among laboratories, patients with the same variant identified at different laboratories may receive conflicting reports on what that genetic anomaly means for their health.
Tools for Sharing Genomic Information
Given how critical the accurate interpretation of genomic data is to patient health, laboratories and clinicians need better resources to help them interpret genomic information accurately. The International Collaboration for Clinical Genomics, through the Clinical Genome (ClinGen) Resource Program, is working to harness the vast amount of genomic information generated by clinical laboratories and researchers to make it publicly available through ClinVar, a database housed in the National Center for Biotechnology Information (NCBI) at the National Institutes of Health (NIH).
ClinVar collects information about genomic variants and their relationships to human health from clinical laboratories and summarizes it for clinicians, researchers, and laboratory professionals. To protect patient privacy, the data is stripped of all identifying information (such as name and date of birth) and precautions are in place to control access.(f) ClinVar differs from other genomic databases in that it is free and publicly available and it focuses on all types of genetic variation, rather than just a particular set of genes. It collects information not only about the final decisions made by laboratories, but also the process by which they interpreted the evidence.
Genomic databases like ClinVar can provide researchers with data to analyze related to a particular disease. Researchers can also identify potential research subjects with rare genomic variants and, through carefully controlled protocols, invite them to participate in a study. By providing access to large amounts of data, genomic databases help laboratories interpret and standardize the results they provide to doctors and patients. The databases can also serve as a quality improvement measure, as a laboratory’s results can be evaluated against its own and other laboratories’ historical data. Clinicians can use genomic databases to compare their patients to others and learn from other patients with the same genomic variants or diseases.(g)
Patients are also getting involved in the movement by sharing their own genomic information and connecting with other patients via genetic registries. While data submitted to ClinVar and similar genomic databases typically comes directly from laboratories, registries collect data directly from patients. Often created by groups representing particular diseases, these registries are designed to gather the kinds of detailed, standardized information researchers need to identify and develop potential therapies and design clinical trials with objectively measurable endpoints. For example, the organization Patient Crossroads has created registries for numerous genetic diseases, including a muscular dystrophy registry with data on over 2,000 patients.
Registries typically ask detailed questions about an individual’s health history and enable storage of genetic tests results and other reports, but the individual chooses what information to enter and share with the public, researchers, and other patients. While registries contain genetic data, they are also rich sources of more general medical information. For example, they may provide health histories that can help clinicians and patients understand the symptoms and progressions of particular conditions.Many patient registries have evolved to include a community component facilitating communication and interaction among individuals with similar diseases or genetic conditions.
Paving the Way for the Genomics Revolution
The ability to sequence the human genome is one of the most significant medical breakthroughs of the last fifty years. But in order to reap the full potential of the DNA revolution, scientists need access to as much genomic data as possible, especially when a variant is too rare for most health providers to have on their own records. Genomic information means little without context, and sharing this information – in a private, regulated way – will have both individual and global benefits. When an individual undergoes genetic testing, a centralized repository of all known information on genomic variants will allow the laboratory to more accurately interpret their results and will help their clinician to develop a more personalized management plan. Ultimately, genomic data sharing will help the scientific community to better understand the relationship between genes and human health, paving the way for new medical breakthroughs and better health for all of us.
The authors would like to acknowledge Danielle Metterville, the ClinGen Resource Program, and the ICCG Education, Ethics, and Engagement Working Group.
Get in touch about this workA secure, centralized workspace where faculty upload notes, papers, and lecture materials—and instantly receive clear, accurate, publication-ready drafts across formats: op-eds, research briefs, executive summaries, pitches, public commentary, and more.
Discover More